BioTuesdays

Category - Markets

Avid Bioservices
Markets

HCW starts Avid Bioservices at buy; PT $5

H.C. Wainwright launched coverage of Avid Bioservices (NASDAQ:CDMO) with a “buy” rating and $5 price target. The stock closed at $3.56 on May 23. Avid has accumulated 25 years of biologics cGMP experience, including...

May 24, 2018
Canaccord Logo
Markets

Canaccord cuts Vermillion to hold; PT to $1

Canaccord Genuity downgraded Vermillion (NASDAQ:VRML) to “hold” from “buy” and lowered its price target to $1 from $2.25 after the company’s first quarter results missed estimates across the board. The stock closed at...

May 24, 2018
Cesca Therapeutics Logo
Markets

HCW starts Cesca Therapeutics at buy; PT $1.50

H.C. Wainwright launched coverage of Cesca Therapeutics (NASDAQ:KOOL) with a “buy” rating and $1.50 price target. The stock closed at 53 cents on May 22. Cesca is focused on cell-based therapies and automated cell...

May 23, 2018
Citius Logo
Markets

HCW starts Citius Pharma at buy; PT $11

H.C. Wainwright initiated coverage of Citius Pharmaceuticals (NASDAQ:CTXR) with a “buy” rating and price target of $11. The stock finished at $2.40 on May 22. The company’s antibiotic lock therapy drug combination, Mino...

May 23, 2018
Synthetic Biologics Logo
Markets

HCW starts Synthetic Biologics at buy; PT $1

H.C. Wainwright initiated coverage of Synthetic Biologics (NYSE AMERICAN:SYN) with a “buy” rating and price target of $1. The stock finished at 25 cents on May 17. Analyst Edward White writes that the new coverage is...

May 21, 2018
Agile Therapeutics
Markets

HCW halves Agile Therapeutics PT to $4

H.C. Wainwright halved its price target for Agile Therapeutics (NASDAQ:AGRX) to $4 from $8 after the company updated the regulatory status of Twirla, its weekly transdermal contraceptive patch. The stock closed at 69...

May 21, 2018
Helius Medical Technologies Logo
Markets

BTIG starts Helius Medical at buy; PT $14

BTIG initiated coverage of Helius Medical Technologies (NASDAQ:HSDT) with a “buy” rating and $14 price target. The stock closed at $11.11 on May 16. “Helius has the potential to help people with traumatic brain injuries...

May 17, 2018
Anavex
Markets

Maxim ups Anavex Life Sciences PT to $7

Maxim Group raised its price target for Anavex Life Sciences (NASDAQ:AVXL) to $7 from $5, after factoring in Anavex 2-73 for additional indications: Rett syndrome and Parkinson’s disease, beyond Alzheimer’s disease. The...

May 16, 2018
Markets

Roth starts Daré Bioscience at buy; PT $6

Roth Capital Partners initiated coverage of Daré Bioscience (NASDAQ:DARE) with a “buy” rating and $6 price target. The stock closed at $1.07 on May 15. Daré brings innovation to the contraception market, writes analyst...

May 16, 2018